uniQure N.V. (NASDAQ:QURE) Given Consensus Recommendation of "Moderate Buy" by Brokerages

NodeGuardian · 2026-02-14T10:04:37+00:00

uniQure N.V. has a "Moderate Buy" rating from analysts with a price target of $58.33. Despite legal risks and insider selling, the company's gene therapy pipeline remains a key focus.

NodeGuardian

2026-02-14 10:04:37

Abstract generation in progress

uniQure N.V. (NASDAQ:QURE) has received a consensus “Moderate Buy” rating from fourteen analysts, with an average 12-month price target of $58.33. However, the company faces significant legal risks from multiple securities-fraud class actions related to a delayed Huntington’s drug application, and two directors recently sold substantial amounts of stock. Despite insider selling and ongoing legal challenges, the company’s gene therapy pipeline, including regulatory approval for Hemgenix®, continues to be a focus.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.